Compare VALN & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VALN | DCTH |
|---|---|---|
| Founded | 2012 | 1988 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.5M | 578.4M |
| IPO Year | 2021 | 2015 |
| Metric | VALN | DCTH |
|---|---|---|
| Price | $6.48 | $16.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $15.50 | ★ $22.00 |
| AVG Volume (30 Days) | 77.9K | ★ 702.7K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $24.54 |
| Revenue Next Year | $93.87 | $33.15 |
| P/E Ratio | ★ N/A | $409.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.75 | $8.12 |
| 52 Week High | $12.23 | $17.42 |
| Indicator | VALN | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 60.79 | 58.70 |
| Support Level | $5.03 | $8.57 |
| Resistance Level | $6.60 | $17.42 |
| Average True Range (ATR) | 0.24 | 0.54 |
| MACD | 0.00 | -0.15 |
| Stochastic Oscillator | 56.42 | 14.96 |
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.